Our studies highlight the broad therapeutic potential of RBM-007 and the multifunctionality of FGF2 (Figure 1) in the treatments of wet AMD, achondroplasia, cancer pain and lung cancer, respectively, while providing perspectives on these therapeutic applicabilities. This evidence concerns the gene FGF2 and wet macular degeneration.